Cargando…

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung

INTRODUCTION: The optimal management of large cell neuroendocrine cancer of the lung (LCNEC) is unclear, and data regarding anti–programmed cell death protein 1 (PD-1) antibodies are scarce. This study reports the clinical efficacy of a PD-1 inhibitor in patients with advanced LCNEC. METHODS: All pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agar, Camille, Geier, Margaux, Léveiller, Guillaume, Lamy, Régine, Bizec, Jean-Louis, Tiercin, Marie, Bernier, Cyril, Robinet, Gilles, Léna, Hervé, Ricordel, Charles, Corre, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474479/ https://www.ncbi.nlm.nih.gov/pubmed/34590004 http://dx.doi.org/10.1016/j.jtocrr.2020.100129

Ejemplares similares

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
por: Amrane, Karim, et al.
Publicado: (2020)

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
por: Renaud, Emmanuelle, et al.
Publicado: (2023)

Sécurité et efficacité de l’immunothérapie selon un schéma double dose dans le CBNPC avancé : étude rétrospective multicentrique IDEE
por: Pierre, C., et al.
Publicado: (2023)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
por: Kanda, Shinichiro, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer
por: Jaksic, Nicolas, et al.
Publicado: (2018)

Effect of Continuous versus Intermittent Subglottic Suctioning on Tracheal Mucosa by the Mallinckrodt TaperGuard Evac Oral Tracheal Tube in Intensive Care Unit Ventilated Patients: A Prospective Randomized Study
por: Seguin, Philippe, et al.
Publicado: (2018)

A brief history of toxicology in France during the last two centuries (1789–1989)
por: Bonnemain, B., et al.
Publicado: (2022)

Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
por: Annic, Josselin, et al.
Publicado: (2022)

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center
por: Pierre, C., et al.
Publicado: (2021)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases
por: Geier, Margaux, et al.
Publicado: (2021)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report
por: Takimoto Sato, Michiko, et al.
Publicado: (2020)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Long‐term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab
por: Oda, Risa, et al.
Publicado: (2020)

Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrine tumor
por: Haque, Waqas, et al.
Publicado: (2020)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: A case report
por: Yan, Bing, et al.
Publicado: (2018)

Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report
por: Takagi, Kuniyasu, et al.
Publicado: (2021)

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
por: Dubus, Margaux, et al.
Publicado: (2023)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2019)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

Neuroendocrine neoplasms: a brief overview emphasizing gastroenteropancreatic tumors
por: Lopes, José Manuel
Publicado: (2017)

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
por: Paraghamian, Sarah E., et al.
Publicado: (2017)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
por: Kang, Nai-Wen, et al.
Publicado: (2021)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
por: Gettinger, Scott N., et al.
Publicado: (2021)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ra126br3h305795u0lt6jia634